Klinički značaj ekspresije matriks metaloproteinaza (MMP)-2 i MMP-9 kod skvamocelularnog karcinoma larinksa
Sažetak
Uvod/Cilj. Prethodna istraživanja sugerišu da matriks-metaloproteinaze (MMP) imaju sposobnost da razgrađuju komponente vanćelijskog matriksa i imaju veliku ulogu u progresiji malignih tumora i nastanku metastaza. Cilj ove studije je bio da se ispita ekspresija MMP-2 i MMP-9 u tkivu skvamocelularnog karcinoma larinksa (SCKL) i da se proceni njihov klinički značaj. Metode. U prospektivnoj studiji, uzorci tumorskog tkiva 70 bolesnika sa SCKL (45 sa karcinomom glotisa i 25 sa karcinomom supraglotisa) i uzoraka tkiva sluznice larinksa 70 bolesnika sa hroničnim laringitisom bojeni su imunohistohemijski na MMP-2 i MMP-9. Ispitivana je povezanost između nivoa imunohistohemijske ekspresije MMP i kliničkih i histoloških karakteristika bolesnika sa SCKL u odnosu na bolesnike sa hroničnim laringitisom. Rezultati. Ekspresija MMP-2 i MMP-9 bila je značajno viša u tkivu glotičnog i supraglotičnog SCKL u odnosu na ekspresiju ispitivanih MMP u tkivu hronično inflamirane sluznice larinksa (p < 0,001 i p < 0,001, redom). Nađena je pozitivna korelacija između epitelne ekspresije MMP-2 i perineuralne invazije (r = 0,515; p < 0,008), limfovaskularne invazije (r = 0,559; p < 0,004) i pojave recidiva bolesti (r = 0,415; p = 0,039) kod supraglotičnog SCKL, kao i između ekspresije MMP-2 i pojave egzofitičnog tipa rasta tumora (r = 0,347; p = 0,020) kod glotičnog SCKL. Ekspresija MMP-9 u epitelu bila je povezana sa limfovaskularnom invazijom (r = 0,331; p = 0,026) i pojavom egzofitičnog tumorskog rasta (r = 0,474; p < 0,001) kod glotičnog SCKL. Zaključak. Endopeptidaze MMP-2 i MMP-9 mogu biti korišćene kao potencijalni biomarkeri za procenu progresije SCKL.
Reference
Smee R, Williams JR, Kotevski DP. Management of locally advanced T3-4 glottic laryngeal carcinomas. J Laryngol Otol 2018; 132(7): 642−50.
Tang D, Tao L, Zhou L, Zhang M, Wu X, Li X, et al. Retrospective analysis of 659 laryngeal squamous cell carcinoma patients treated with open laryngeal function-preserving operations. Acta Otolaryngol 2018; 138(11): 1043−50.
Whittaker M, Ayscough A. Matrix metalloproteinases and their inhibitors: current status and future challenges. Celltransmissions 2001; 17(1): 3−14.
Gou X, Chen H, Jin F, Wu W, Li Y, Long J, et al. Expressions of CD147, MMP-2 and MMP-9 in laryngeal carcinoma and its correlation with poor prognosis. Pathol Oncol Res 2014; 20(2): 475−81.
Rydlova M, Holubec L Jr, Ludvikova M Jr, Kalfert D, Franekova J, Povysil C, et al. Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res 2008; 28(2B): 1389−97.
Deschler DG, Moore MG, Smith RV. Quick Reference Guide to TNM Staging of Head and Neck Cancer and Neck Dissection Classification, 5th ed. Alexandria, VA: American Academy of Otolaryngology – Head and Neck Surgery Foundation; 2014.
Peschos D, Damala C, Stefanou D, Tsanou E, Assimakopoulos D, Vougiouklakis T, et al. Expression of matrix metalloproteinase-9 (gelatinase B) in benign, premalignant and malignant laryngeal lesions. Histol Histopathol 2006; 21(6): 603−8.
Uloza V, Liutkevicius V, Pangonyte D, Lesauskaite V. Characteristics of expression of matrix metalloproteinases (MMP-2 and MMP-9) in glottic squamous cell carcinoma and benign vocal fold lesions. Clin Exp Otorhinolaryngol 2015; 8(1): 57−64.
Lotfi A, Mohammadi G, Saniee L, Mousaviagdas M, Chavoshi H, Tavassoli A. Serum level of matrix metalloproteinase-2 and -9 in patients with laryngeal squamous cell carcinoma and clinical significance. Asian Pac J Cancer Prev 2015; 16(4): 1327−30.
Liu WW, Zeng ZY, Wu QL, Hou JH, Chen YY. Overexpression of MMP-2 in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Otolaryngol Head Neck Surg 2005; 132(3): 395−400.
Wael S, Manal S. Expression of nm23H1 and MMP2 in laryngeal carcinoma and its role in aggressiveness of the tumour and node metastasis. Egypt J Otolaryngol 2013; 29(2): 86−92.
Akdeniz O, Akduman D, Haksever M, Ozkarakas H, Muezzinoglu B. Relationships between clinical behavior of laryngeal squamous cell carcinomas and expression of VEGF, MMP-9 and E-cadherin. Asian Pac J Cancer Prev 2013; 14(9): 5301−10.
Sarioglu S, Ozer E, Kirimca F, Sis B, Pabuccuoglu U. Matrix metalloproteinase-2 expression in laryngeal preneoplastic and neoplastic lesions. Pathol Res Pract 2001; 197(7): 483−6.
Yuce I, Bayram A, Caglı S, Canoz O, Bayram S, Guney E. The role of CD44 and matrix metalloproteinase-9 expression in predicting neck metastasis of supraglottic laryngeal carcinoma. Am J Otolaryngol 2011; 32(2): 141−6.
Mallis A, Teymoortash A, Mastronikolis NS. MMP-2 expression in 102 patients with glottic laryngeal cancer. Eur Arch Otorhinolaryngol 2012; 269(2): 639−42.
Cao XL, Xu RJ, Zheng YY. Expression of type IV collagen, metalloproteinase-2, metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in laryngeal squamous cell carcinomas. Asian Pac J Cancer Prev 2011; 12(12): 3245−9.
Wittekindt C, Jovanovic N, Guntinas-Lichius O. Expression of matrix metalloproteinase-9 (MMP-9) and blood vessel density in laryngeal squamous cell carcinomas. Acta Otolaryngol 2011; 131(1): 101−6.
Colovic Z, Pesutić-Pisac V, Poljak NK, Racić G, Cikojević D, Kontić M. Expression of matrix metalloproteinase-9 in patients with squamous cell carcinoma of the larynx. Coll Antropol 2013; 37(1): 151−5.
Kalfert D, Ludvikova M, Topolcan O, Windrickova J, Malirova E, Pesta M, et al. Analysis of preoperatice serum levels of MMP-1, -2, -9 in patients with site-specific head and neck squamous cell cancer. Anticancer Res 2014; 34(12): 7431−41.
Li JZ, Gao W, Lei WB, Zhao J, Chan JY, Wei WI, et al. MicroRNA 744-3p promotes MMP-9 mediated metastasis by simultaneously suppressing PDCD4 and PTEN in laryngeal squamous cell carcinoma. Oncotarget 2016; 7(36): 58218−23.
Popov TM, Stancheva G, Goranova TE, Rangachev J, Konov D, Todorov S, et al. Strong correlation between mRNA expression levels of HIF-2α, VEGFR1, VEGFR2 and MMP2 in laryngeal carcinoma. Pathol Oncol Res 2016; 22(4): 741−6.